Related Experiment Video
Updated: Jul 10, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells
Clarissa S Craft1, Li Xu, Diana Romero
1Division of Hematology/Oncology, Department of Medicine, Northwestern University, Olson 8321, 710 North Fairbanks, Chicago, IL 60610-3008, USA.
Abstract:
Genistein has been shown to inhibit human prostate cancer (PCa) cell motility. Endoglin has been identified as an important suppressor of PCa cell motility, and its expression is lost during PCa progression. It is therefore important to determine whether endoglin loss affects genistein's efficacy and, if so, by what mechanism. In the current study, genistein was shown to induce reversion of endoglin-deficient cells to a low motility, endoglin-replete phenotype. Because endoglin suppresses PCa cell motility in an activin-like kinase receptor-2 (ALK2)- and Smad1-dependent manner, we sought to determine whether genistein was activating the ALK2-Smad1 pathway. Although treatment with genistein or overexpression of Smad1 or ALK2 all increased Smad1-responsive promoter activity and decreased cell motility, genistein's efficacy was abrogated by either Smad1 or ALK2 knockdown. Furthermore, transfection of cells with a kinase dead mutant of ALK2 abrogated genistein's efficacy. Together, these findings demonstrate that genistein therapeutically induces reversion to a low-motility phenotype in aggressive endoglin-deficient PCa cells. It does so by activating ALK2-Smad1 endoglin-associated signaling. These findings support the notion that individuals with low endoglin-expressing PCa will benefit from genistein treatment.
Insights
Genistein reactivates suppressed prostate cancer cell motility pathways by targeting endoglin signaling. This suggests genistein may benefit patients with low endoglin expression in their prostate cancer.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- Genistein inhibits prostate cancer (PCa) cell motility.
- Endoglin suppresses PCa cell motility but is lost during PCa progression.
- The mechanism by which genistein affects endoglin-deficient PCa cells is unclear.
Purpose of the Study:
- To determine if endoglin loss affects genistein's efficacy in prostate cancer.
- To elucidate the molecular mechanism underlying genistein's action in endoglin-deficient PCa cells.
Main Methods:
- Genistein treatment of endoglin-deficient PCa cells.
- Assessment of cell motility and endoglin re-expression.
- Investigated the role of activin-like kinase receptor-2 (ALK2) and Smad1 signaling pathway activation.
- Utilized gene knockdown (Smad1, ALK2) and kinase-dead ALK2 mutant transfection.
Main Results:
- Genistein induced reversion of endoglin-deficient cells to a low-motility, endoglin-replete phenotype.
- Genistein's efficacy was dependent on the ALK2-Smad1 pathway, as abrogated by knockdown or kinase-dead mutants.
- Genistein activated Smad1-responsive promoter activity and decreased cell motility.
Conclusions:
- Genistein therapeutically induces a low-motility phenotype in aggressive endoglin-deficient PCa cells.
- Genistein acts by activating the ALK2-Smad1 endoglin-associated signaling pathway.
- Patients with low endoglin-expressing PCa may benefit from genistein treatment.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:38Mitogens and the Cell Cycle
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...